Michael is a senior life sciences executive with 30 years of commercial, business development and capital markets experience. Most recently, he served as Vice President, Global Business Development and Alliance Management at Orexigen Therapeutics, Inc., where he led global business development activities to license Orexigen assets and manage alliance partners. Previously, Michael was CEO of Senté, Inc., a privately held company and leader in medical skincare products, and a senior advisor for MKO Global Partners, L.P. Earlier in his career, Michael held roles of increasing responsibility at Amylin Pharmaceuticals, including Vice President, Specialty and Rare Disease Unit, and Senior Director, Finance, Investor Relations. Michael also held leadership positions at Santarus, Inc., Amgen and AstraZeneca. Michael received a BA in public administration and economics from San Diego State University and an MBA from the University of Redlands.